EX-16.1 2 gtletterexhibit161.htm EXHIBIT 16.1

Exhibit

[Grant Thornton LLP Letterhead]

August 25, 2016

U.S. Securities and Exchange Commission

Office of the Chief Accountant

100 F Street, NE

Washington, DC 20549

Re: Ligand Pharmaceuticals, Inc.

File No. 001-33093

Dear Sir or Madam:

We have read Item 4.01 of Form 8-K of Ligand Pharmaceuticals, Inc. dated August 25, 2016, and agree with the statements concerning our Firm contained therein.

Very truly yours,

/s/ GRANT THORNTON LLP